Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1995-10-19
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1053-0770
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
351-2
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:7669975-Amrinone,
pubmed-meshheading:7669975-Cardiac Output,
pubmed-meshheading:7669975-Cardiotonic Agents,
pubmed-meshheading:7669975-Drug Combinations,
pubmed-meshheading:7669975-Humans,
pubmed-meshheading:7669975-Mitral Valve,
pubmed-meshheading:7669975-Phosphodiesterase Inhibitors
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Does amrinone reduce the need for other positive inotropes?
|
| pubmed:publicationType |
Letter,
Comment
|